TNM002

DRUG3 trials

Sponsors

Zhuhai Trinomab Pharmaceutical Co., Ltd.

Conditions

Healthy VolunteersTetanus

Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults

CompletedNCT05842798

Zhuhai Trinomab Pharmaceutical Co., Ltd.Healthy Volunteers

Start: 2021-10-15End: 2022-02-24Updated: 2023-05-06

A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine

CompletedNCT06607380

Zhuhai Trinomab Pharmaceutical Co., Ltd.Tetanus

Start: 2022-08-13End: 2023-04-17Updated: 2024-09-23

Phase 3

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

CompletedNCT05664750

Zhuhai Trinomab Pharmaceutical Co., Ltd.Tetanus

Start: 2022-12-22End: 2023-07-07Updated: 2024-03-08

Related Papers

Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial

Nature Medicine2025-07-082 citations